Industry-chain Research Brief

Qingdao Yibang Biotechnology Co., Ltd.: Biomedicine Brief

Qingdao · Biomedicine · 2026-06-14

English company profile Full Chinese report All report summaries

English Summary

Qingdao Yibang Biotechnology Co., Ltd. is indexed in the China Little Giant company database. The Chinese legal name is 青岛易邦生物工程有限公司. The profile is associated with Qingdao. The report is grouped under Biomedicine. Recognition context: 2020 2nd batch. Chinese source report date: 2026-06-14. 6 public evidence links are available on this page or in the Chinese report. The English brief covers company profile, product direction, industry-chain role, patent and R&D signals, scale indicators and policy-material checkpoints, with internal links to the company page, Chinese source report and related topic hubs.

Report Snapshot

CompanyQingdao Yibang Biotechnology Co., Ltd.
RegionQingdao
IndustryBiomedicine
Published2026-06-14
Chinese reportOpen
CompanyQingdao Yibang Biotechnology Co., Ltd.
Region / IndustryQingdao · Biomedicine
Recognition2020 2nd batch
Patent signal390 patent-related records

Company and Recognition Snapshot

Qingdao Yibang Biotechnology Co., Ltd. is indexed as a national-level Little Giant enterprise in Qingdao. The English profile places the company under Biomedicine and records 2020 2nd batch as the available recognition context.

Recognition batch2020 2nd batch
RegionQingdao
IndustryBiomedicine
Registered capitalRMB 55.00 million
Employee signal957 employees
Listed statusNot listed
Patent signal390 patent-related records
R&D signalR&D investment detail not published in the English dataset

Business and Industry-chain Position

Chinese public records indicate R&D, design and engineering activity. The recorded industry-chain position is Biomedicine and medical devices / Recorded position. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.

Technology, Patent and R&D Signals

The public profile records 390 patent-related records. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.

Policy-material Review Points

  • Verify whether the company's main business, niche market and product evidence all point to Biomedicine.
  • Check that patent, R&D, employee and financial fields support the same core product direction.
  • Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
  • Use the linked Chinese source report for original-language evidence and source links.

Original Report and Profile

For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.

Related Search Paths